Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world study reveals optimal strategies for breast cancer patients resistant to leading drugs

NCT ID NCT07587983

Knowledge-focused Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 220 women with HER2-low advanced breast cancer whose disease progressed after antibody-drug conjugate (ADC) therapy. Researchers compared different follow-up treatments, such as other ADCs, chemotherapy, hormone therapy, or immunotherapy, to see which worked best. The goal is to help doctors choose the most effective next step for these patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

220 people

The number who actually took part.

Started

Mar 2018

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with histologically confirmed HER2-low advanced or metastatic breast cancer who received antibody-drug conjugate (ADC) therapy in the advanced setting and subsequently experienced disease progression.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * females aged ≥18 years. * confirmed pathologic diagnosis of HER2-low MBC (defined as HER2 IHC 1+ or 2+ without gene amplification by FISH detection). * patients had disease progression following ADC treatment in advanced setting and had undergone at least one available efficacy evaluation. * patients received at least one subsequent anti-tumor treatment following ADC failure, with at least one available efficacy evaluation. Exclusion Criteria: * patients previously treated with ADC during neoadjuvant or adjuvant setting. * patients who had not experienced disease progression on their first ADC (ADC1) regimen and remained on ADC1 treatment. * patients with no documented subsequent anti-tumor therapy following ADC1 treatment. * patients who lacked evaluable efficacy assessment data during ADC1 or post-ADC therapy. * patients with incomplete clinicopathological information.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • The First Affiliated Hospital with Nanjing Medical University

    Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.